Rodrigo Alejandro Santibáñez Moreira
Behavioral Neurologist
Pontificia Universidad Católica de Chile
Santiago, Chile
Behavioral Neurology, Cognitive Neurology, Dementia, Neurodegeneration, Alzheimer's Disease, Frontotemporal dementias, Autoimmune encephalitis
-
Neurology, UNIVERSITY OF BRITISH COLUMBIA. Canada, 2017
-
Neurology, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 2015
-
Doctor of Medicine, UNIVERSIDAD AUSTRAL DE CHILE. Chile, 2006
-
Medicine, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 2006
-
Instructor Full Time
PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
Medicine
Santiago, Chile
2015 - At present
-
Behavioral Neurologist Part Time
Complejo Asistencial Doctor Sótero del Río
Santiago, Chile
2017 - 2024
-
Behavioral Neurologist Full Time
Red de Salud UC-Christus
Santiago, Chile
2017 - At present
-
Neurologist Part Time
Complejo Asistencial Doctor Sótero del Río
Santiago, Chile
2015 - 2017
-
Primary Care Physician Full Time
Servicio de Salud Osorno
Osorno, Chile
2007 - 2015
-
Instructor adjunto de neurología Full Time
Pontificia Universidad Católica de Chile
Santiago, Chile
2018 - At present
A Woman with Progressive Episodic Memory Loss and Personality Change |
Diagnóstico diferencial de otras demencias |
Semiología de las demencias |
COVID-19 in older people with cognitive impairment in Latin America |
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE) |
Mind Care Lab=> A Digital Tool for Early Detection of Cognitive Impairment |
Transcranial Magnetic Stimulation in Nonfluent/Agrammatic Variant Primary Progressive Aphasia |
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease (MINT-01) |
Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) |
CREAD Study=> A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) |
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) |
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (AMARANTH) |
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4 Study) |
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) |